2-[[4-(3-Oxopentan-2-yl)phenyl]methyl]cyclopentan-1-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-[[4-(3-Oxopentan-2-yl)phenyl]methyl]cyclopentan-1-one
• 英文别名: 2-[[4-(3-oxopentan-2-yl)phenyl]methyl]cyclopentan-1-one
• 化学式: C₁₇H₂₂O₂
• 分子量: 258.35
• InChiKey: RZUFTVLHTCBHAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] HYDROGELATORS COMPRISING D-AMINO ACIDS<br/>[FR] COMPOSÉS FORMANT DES HYDROGELS COMPRENANT DES ACIDES AMINÉS D
  申请人：UNIV BRANDEIS

  公开号：WO2014074789A1

  公开（公告）日：2014-05-15

  Described herein are compounds comprising an oligopeptide and a non-steroidal antiinflammatory agent. The compounds self-assemble into supramolecular hydrogels and can be used as topical treatments for inflammatory conditions, such as osteoarthritis. Also described herein are oligopeptides compounds made from D-amino acid residues that form supramolecular hydrogels. The compounds may be functionalized with active agents, such as anticancer therapeutic agents, antiinflammatory agents, or imaging agents, therefore providing new mechanisms for delivery of active agents.

  本文描述了包含寡肽和非甾体抗炎药物的化合物。这些化合物自组装成超分子水凝胶，可用作治疗炎症病症，如骨关节炎的局部治疗。本文还描述了由D-氨基酸残基制成的寡肽化合物，形成超分子水凝胶。这些化合物可以与活性剂（如抗癌治疗剂、抗炎药物或成像剂）功能化，从而提供了传递活性剂的新机制。
• COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS
  申请人：MEDICON PHARMACEUTICALS, INC.

  公开号：US20190343848A1

  公开（公告）日：2019-11-14

  The invention relates to compositions and methods for treating ophthalmic conditions.
• ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF
  申请人：MEDICON PHARMACEUTICALS, INC.

  公开号：US20200246330A1

  公开（公告）日：2020-08-06

  Compounds of the general Formula A-D-Y are disclosed with activity towards treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. Pharmaceutical compositions, methods of making, and methods of use thereof are also described.